Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Università degli Studi di Ferrara
- Target Recruit Count
- 522
- Registration Number
- NCT01512953
- Locations
- 🇮🇹
University Hospital of Ferrara, Ferrara, ER, Italy
Efficacy Study of Ilaprazole to Treat Erosive Esophgitis
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2012-01-12
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 292
- Registration Number
- NCT01509261
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
- Conditions
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 650
- Registration Number
- NCT01505127
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 607
- Registration Number
- NCT01459367
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
- Conditions
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 406
- Registration Number
- NCT01456260
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
- Conditions
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 439
- Registration Number
- NCT01456247
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
- Conditions
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 642
- Registration Number
- NCT01452750
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 482
- Registration Number
- NCT01452711
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 409
- Registration Number
- NCT01452698
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
- Conditions
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 621
- Registration Number
- NCT01452763
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.